Gilead racing to FDA with a new HIV cocktail boasting megablockbuster potential
Gilead’s R&D team brought home a clean sweep for its four Phase III studies adding the experimental drug bictegravir to its backbone HIV therapy.
Their cocktail therapy adding bictegravir to its mainstays emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) proved non-inferior to dolutegravir and other antiretroviral therapies in the 4 late-stage studies, setting up a new drug application in a matter of weeks as Gilead races to a near-term marketing OK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.